BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27448975)

  • 1. Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand.
    Amoury M; Bauerschlag D; Zeppernick F; von Felbert V; Berges N; Di Fiore S; Mintert I; Bleilevens A; Maass N; Bräutigam K; Meinhold-Heerlein I; Stickeler E; Barth S; Fischer R; Hussain AF
    Oncotarget; 2016 Aug; 7(34):54925-54936. PubMed ID: 27448975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
    Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A specific photoimmunotheranostics agent to detect and eliminate skin cancer cells expressing EGFR.
    von Felbert V; Bauerschlag D; Maass N; Bräutigam K; Meinhold-Heerlein I; Woitok M; Barth S; Hussain AF
    J Cancer Res Clin Oncol; 2016 May; 142(5):1003-11. PubMed ID: 26847542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and Specific Elimination of EGFR
    Bauerschlag D; Meinhold-Heerlein I; Maass N; Bleilevens A; Bräutigam K; Al Rawashdeh W; Di Fiore S; Haugg AM; Gremse F; Steitz J; Fischer R; Stickeler E; Barth S; Hussain AF
    Pharm Res; 2017 Apr; 34(4):696-703. PubMed ID: 28074431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate.
    Mungra N; Biteghe FAN; Malindi Z; Huysamen AM; Karaan M; Hardcastle NS; Bunjun R; Chetty S; Naran K; Lang D; Richter W; Hunter R; Barth S
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):12203-12225. PubMed ID: 37432459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment.
    Zhang C; Sheng W; Al-Rawe M; Mohiuddin TM; Niebert M; Zeppernick F; Meihold-Heerlein I; Hussain AF
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells.
    De Groof TWM; Mashayekhi V; Fan TS; Bergkamp ND; Sastre Toraño J; van Senten JR; Heukers R; Smit MJ; Oliveira S
    Mol Pharm; 2019 Jul; 16(7):3145-3156. PubMed ID: 31244224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy.
    Palasuberniam P; Yang X; Kraus D; Jones P; Myers KA; Chen B
    Sci Rep; 2015 Aug; 5():13298. PubMed ID: 26282350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells.
    Hussain AF; Kampmeier F; von Felbert V; Merk HF; Tur MK; Barth S
    Bioconjug Chem; 2011 Dec; 22(12):2487-95. PubMed ID: 21995499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.
    Eng MS; Kaur J; Prasmickaite L; Engesæter BØ; Weyergang A; Skarpen E; Berg K; Rosenblum MG; Mælandsmo GM; Høgset A; Ferrone S; Selbo PK
    Photochem Photobiol Sci; 2018 May; 17(5):539-551. PubMed ID: 29565434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells.
    Khandelwal S; Boylan M; Spallholz JE; Gollahon L
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fine Tuning Antibody Conjugation Methods using SNAP-tag Technology.
    Chouman K; Woitok M; Mladenov R; Kessler C; Weinhold E; Hanz G; Fischer R; Meinhold-Heerlein I; Bleilevens A; Gresch G; Haugg AM; Zeppernick F; Bauerschlag D; Maass N; Stickeler E; Kolberg K; Hussain AF
    Anticancer Agents Med Chem; 2017; 17(10):1434-1440. PubMed ID: 28270070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
    Williams CB; Soloff AC; Ethier SP; Yeh ES
    Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates.
    van Lith SAM; van den Brand D; Wallbrecher R; Wübbeke L; van Duijnhoven SMJ; Mäkinen PI; Hoogstad-van Evert JS; Massuger L; Ylä-Herttuala S; Brock R; Leenders WPJ
    Eur J Pharm Biopharm; 2018 Mar; 124():63-72. PubMed ID: 29274374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
    Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
    J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F.
    Woitok M; Klose D; Niesen J; Richter W; Abbas M; Stein C; Fendel R; Bialon M; Püttmann C; Fischer R; Barth S; Kolberg K
    Cancer Lett; 2016 Oct; 381(2):323-30. PubMed ID: 27502168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indocyanine green loaded liposome nanocarriers for photodynamic therapy using human triple negative breast cancer cells.
    Shemesh CS; Hardy CW; Yu DS; Fernandez B; Zhang H
    Photodiagnosis Photodyn Ther; 2014 Jun; 11(2):193-203. PubMed ID: 24657627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of a nanomedicine-based silicon phthalocyanine 4 photodynamic therapy (Pc 4-PDT) strategy for targeted treatment of EGFR-overexpressing cancers.
    Master AM; Livingston M; Oleinick NL; Sen Gupta A
    Mol Pharm; 2012 Aug; 9(8):2331-8. PubMed ID: 22775587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.